ICU Medical (NASDAQ:ICUI) Director David Greenberg Sells 2,424 Shares

ICU Medical, Inc. (NASDAQ:ICUI) Director David Greenberg sold 2,424 shares of ICU Medical stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

ICU Medical Price Performance

NASDAQ:ICUI opened at $122.04 on Thursday. The business’s 50-day moving average is $126.79 and its 200 day moving average is $138.45. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $160.29. The company has a market capitalization of $3.05 billion, a P/E ratio of 65.97, a P/E/G ratio of 1.78 and a beta of 0.74. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. During the same quarter last year, the business posted $1.72 EPS. The firm’s revenue for the quarter was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, equities research analysts forecast that ICU Medical, Inc. will post 6.31 earnings per share for the current fiscal year.

Institutional Trading of ICU Medical

Several hedge funds and other institutional investors have recently bought and sold shares of ICUI. Hilton Head Capital Partners LLC purchased a new position in ICU Medical during the fourth quarter worth $32,000. Covestor Ltd raised its stake in shares of ICU Medical by 70.7% in the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 236 shares during the period. Strs Ohio lifted its holdings in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of ICU Medical during the 4th quarter worth about $120,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ICUI. KeyCorp reduced their price target on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday. Finally, Piper Sandler lowered their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $169.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.